EANS-News: Marinomed Biotech AG announces result of conversion ofconvertible bonds

Corporate news transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.

No Keyword

Vienna – 18 February 2019. Marinomed Biotech AG announces that by the end of the conversion period on 14 February 2019 (16:00 CET), conversion notices for nominal value of EUR 6.98 million of the 4% Bonds 2017-2021 with Conditional Conversion Rights, ISIN AT0000A1WD52 (equivalent to approximately 99.7% of the outstanding volume of the convertible bonds), have been submitted for conversion into new shares of Marinomed Biotech AG. Following the issuance of the new shares, the total number of shares will increase by 170,772 new shares to 1,430,772 (corresponding to an increase in share capital of around 13.6%). The free float rises to around 39% (assuming full exercise of the greenshoe option). The issuance and start of trading of the new shares from the convertible bonds are scheduled for 20 February 2019.

Andreas Grassauer, CEO of Marinomed:“The successful IPO and the high conversion rate confirm that we provide an attractive story for investors with our innovative platforms. We welcome all new shareholders and look forward to working with them to further advance our success story.“

About Marinomed Biotech AG
Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the development of innovative products derived from patent protected technology platforms to treat respiratory and ophthalmic conditions. The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. Further information is available at www.marinomed.com.

end of announcement euro adhoc

issuer: Marinomed Biotech AG
Veterinärplatz 1
A-1210 Wien
phone: 0043250774460
FAX: 0043250774493
mail: office@marinomed.com
WWW: www.marinomed.com
ISIN: ATMARINOMED6, AT0000A1WD52
indexes:
stockmarkets: Wien
language: English

Digital press kit: http://www.ots.at/pressemappe/31479/aom

Eva Prieschl-Grassauer
PhD Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
Tel.: +43 (0)1 250 77 4460
E-mail: eva.prieschl@marinomed.com
http://www.marinomed.com

Roland Mayrl
Managing Partner, Metrum Communications
Prinz-Eugen-Straße 80/16, 1040 Vienna, Austria
Tel.: +43 (0) 1 504 69 87 331
E-mail: r.mayrl@metrum.at
http://www.metrum.at

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender